Legal & General Group
VINC

Legal & General Group’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Legal & General Group’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-68
Closed -$2K – 3501
2022
Q2 		$2K Sell
68
-21
-24% -$934 ﹤0.01% 3494
2022
Q1 		$7K Hold
89
– – ﹤0.01% 3474
2021
Q4 		$18K Buy
89
+21
+31% +$5.24K ﹤0.01% 3316
2021
Q3 		$22K Buy
68
+41
+152% +$12K ﹤0.01% 3254
2021
Q2 		$7K Buy
+27
New +$8.23K ﹤0.01% 3449

Other funds holding VINC

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Legal & General Group's VINC Position: Q3 2022 in Review

Legal & General Group sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q3 2022, closing a stake of 68 shares — an estimated $2K sold.

Legal & General Group first reported a position in VINC in Q2 2021 and held it in 5 quarters. The position peaked at $22K in Q3 2021. 42 funds tracked by Wall St. Rank hold VINC as of Q3 2022.

  • Legal & General Group reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Legal & General Group sold 68 Vincerx Pharma, Inc. Common Stock shares in Q3 2022, an estimated $2K.
  • Legal & General Group first reported a position in Vincerx Pharma, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
  • Legal & General Group's Vincerx Pharma, Inc. Common Stock position peaked at $22K in Q3 2021.
  • 42 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q3 2022.

Based on Legal & General Group's 13F filing for Q3 2022, filed 14 Nov 2022.